BRIEF published on 05/04/2026 at 14:51, 4 months 7 days ago Worksport to Present at D. Boral 2026 Global Conference Revenue Growth Institutional Investors Clean Energy Products Worksport Ltd. D. Boral Conference
BRIEF published on 05/04/2026 at 14:51, 4 months 7 days ago Worksport présentera ses travaux à la conférence mondiale D. Boral 2026. Investisseurs Institutionnels Croissance Des Revenus Worksport Ltd. Conférence D. Boral Produits D'énergie Propre
BRIEF published on 05/04/2026 at 14:40, 4 months 7 days ago Bitmine Immersion Technologies Reports $13.1 Billion in Crypto and Cash Holdings Ethereum Crypto Holdings Bitmine Immersion Technologies Staking Platform NYSE Uplisting
BRIEF published on 05/04/2026 at 14:40, 4 months 7 days ago Bitmine Immersion Technologies déclare détenir 13,1 milliards de dollars en cryptomonnaies et en espèces. Ethereum Technologies D'immersion Bitmine Plateforme De Staking Avoirs En Cryptomonnaie Cotation À La Bourse De New York
BRIEF published on 05/04/2026 at 14:35, 4 months 7 days ago NanoViricides' NV-387 Receives Orphan Drug Designation for Measles Treatment NanoViricides NV-387 Orphan Drug Designation Measles Treatment US FDA
BRIEF published on 05/04/2026 at 14:35, 4 months 7 days ago Le NV-387 de NanoViricides obtient la désignation de médicament orphelin pour le traitement de la rougeole NanoViricides NV-387 Désignation De Médicament Orphelin FDA Américaine Traitement De La Rougeole
BRIEF published on 05/04/2026 at 14:35, 4 months 7 days ago Jaguar Health Launches Neonorm Dog for Pet Digestive Health Companion Animals Jaguar Health Gut Health Plant-based Neonorm Dog
BRIEF published on 05/04/2026 at 14:35, 4 months 7 days ago Caldwell Partners Announces Approval for Share Buyback Program Shareholder Value Share Buyback Market Conditions Caldwell Partners TSX Approval
BRIEF published on 05/04/2026 at 14:35, 4 months 7 days ago Caldwell Partners annonce l'approbation de son programme de rachat d'actions Rachat D'actions Valeur Actionnariale Conditions Du Marché Approbation De La TSX Associés Caldwell
BRIEF published on 05/04/2026 at 14:35, 4 months 7 days ago Jaguar Health lance Neonorm Dog pour la santé digestive des animaux de compagnie Jaguar Health Santé Intestinale À Base De Plantes Animaux De Compagnie Chien Néonormal
Published on 09/11/2026 at 17:00, 3 hours 10 minutes ago Critical Elements Selected for Canada Investment Summit Prospectus, Showcasing Project to Leading Global Investors
Published on 09/11/2026 at 17:00, 3 hours 10 minutes ago Critical Elements sélectionné pour inclusion dans le prospectus du sommet Canadien de l'investissement, mettant le projet en valeur auprès d'investisseurs mondiaux de premier plan
Published on 09/11/2026 at 15:25, 4 hours 45 minutes ago Revolve Signs Agreement to Acquire 9.6 MW Operating Wind Project in the US and Secures Project-Level Debt Financing with EDC and Vancity
Published on 09/11/2026 at 15:00, 5 hours 10 minutes ago Regentis Biomaterials Reports First Half 2026 Financial Results and Provides Corporate Update
Published on 09/11/2026 at 14:30, 5 hours 40 minutes ago AIAI Holdings Enters into Extended Lock-up Agreements to Protect Long-Term Stockholder Value
Published on 09/11/2026 at 19:44, 25 minutes ago DocMorris announces final conversion price and issue size of its New Convertible Bonds due 2031
Published on 09/11/2026 at 18:15, 1 hour 54 minutes ago CGTN: How BRICS creates new opportunities for Global South development
Published on 09/11/2026 at 18:00, 2 hours 10 minutes ago ROCTOOL: INFORMATION MENSUELLE RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET ACTIONS COMPOSANT LE CAPITAL SOCIAL
Published on 09/11/2026 at 07:00, 13 hours 10 minutes ago Transparantiekennisgeving van Baltisse Groep
Published on 09/11/2026 at 07:00, 13 hours 10 minutes ago Transparency notification by Baltisse Group
Published on 09/11/2026 at 07:00, 13 hours 10 minutes ago BIOPHYTIS ANNOUNCES COMPLETION OF €5.3 MILLION CAPITAL INCREASE TO FUND ITS PHASE 2 TRIAL IN OBESITY
Published on 09/11/2026 at 07:00, 13 hours 10 minutes ago BIOPHYTIS ANNONCE LA RÉALISATION D’UNE AUGMENTATION DE CAPITAL DE 5,3 MILLIONS D’EUROS DESTINÉE À FINANCER SON ESSAI DE PHASE 2 DANS L’OBÉSITÉ
